JP Morgan Maintains Overweight on Sage Therapeutics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sage Therapeutics (NASDAQ:SAGE) and raises the price target from $24 to $29.

March 26, 2024 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sage Therapeutics and raises the price target from $24 to $29.
The increase in the price target by a reputable analyst such as Anupam Rama from JP Morgan is a strong positive signal for Sage Therapeutics. It suggests a bullish outlook on the company's future performance and potential growth, likely leading to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100